Last reviewed · How we verify
Infuvite Adult (alpha-tocopherol acetate)
At a glance
| Generic name | alpha-tocopherol acetate |
|---|---|
| Sponsor | Novartis |
| Drug class | Vitamin C [EPC] |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2000 |
Approved indications
Boxed warnings
- WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.
Common side effects
- Allergic sensitization
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Vitamin E Dosing Study (PHASE2)
- Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women (PHASE1)
- Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1 (NA)
- Vitamin E Plus Mefenamic Acid Versus Mefenamic Acid Alone for Treating Primary Dysmenorrhea in Women (PHASE4)
- Postpartum Vaginal Estrogen for Breastfeeding Patients (PHASE4)
- Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation (PHASE2)
- PentoxIfylline and Tocopherol for the Treatment of Post-radiotherapy Fibrosis in Head and Neck Cancer Patients (PHASE1)
- Vitamin E Supplementation As Adjunctive Therapy To Lower Inflammation In COVID-19 Patients (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infuvite Adult CI brief — competitive landscape report
- Infuvite Adult updates RSS · CI watch RSS
- Novartis portfolio CI